Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced it will release its fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, February 26, 2025.
The company will host a conference call at 4:30 p.m. E.T. to discuss the results. The event will be webcast live on Sarepta's investor relations website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for access.
Sarepta Therapeutics (NASDAQ:SRPT), un leader nella medicina genetica di precisione per le malattie rare, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del Nasdaq Global Market il mercoledì 26 febbraio 2025.
La società terrà una conferenza telefonica alle 16:30 E.T. per discutere i risultati. L'evento sarà trasmesso in diretta sul sito web delle relazioni con gli investitori di Sarepta, con una registrazione disponibile per un anno. I partecipanti telefonici devono registrarsi online per ricevere i dettagli per la chiamata e un PIN personale per l'accesso.
Sarepta Therapeutics (NASDAQ:SRPT), un líder en medicina genética de precisión para enfermedades raras, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del Nasdaq Global Market el miércoles 26 de febrero de 2025.
La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. E.T. para discutir los resultados. El evento se transmitirá en vivo en el sitio web de relaciones con inversores de Sarepta, con una repetición disponible durante un año. Los participantes por teléfono deben registrarse en línea para recibir los detalles de la llamada y un PIN personal para acceder.
사렙타 테라퓨틱스(SAREPTA THERAPEUTICS, NASDAQ:SRPT)는 희귀 질환을 위한 정밀 유전자 의학의 선두주자로서 2024년 4분기 및 연간 재무 결과를 2025년 2월 26일 수요일 나스닥 글로벌 마켓이 종료된 후 발표할 것이라고 발표했습니다.
회사는 동부 표준시 오후 4시 30분에 결과를 논의하기 위한 전화 회의를 개최할 예정입니다. 이 이벤트는 사렙타의 투자자 관계 웹사이트에서 실시간으로 웹캐스트되며, 1년 동안 재생할 수 있습니다. 전화 참가자는 접속을 위한 다이얼 인 세부정보와 개인 PIN을 받기 위해 온라인으로 등록해야 합니다.
Sarepta Therapeutics (NASDAQ:SRPT), un leader dans la médecine génétique de précision pour les maladies rares, a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la fermeture du Nasdaq Global Market le mercredi 26 février 2025.
La société animera une conférence téléphonique à 16h30 E.T. pour discuter des résultats. L'événement sera diffusé en direct sur le site Web des relations avec les investisseurs de Sarepta, avec une rediffusion disponible pendant un an. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les détails de connexion et un code PIN personnel pour accéder.
Sarepta Therapeutics (NASDAQ:SRPT), ein führendes Unternehmen in der präzisen Gentherapie für seltene Krankheiten, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 nach dem Schluss des Nasdaq Global Market am Mittwoch, den 26. Februar 2025 veröffentlichen wird.
Das Unternehmen wird um 16:30 Uhr E.T. eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Die Veranstaltung wird live auf der Investor-Relations-Website von Sarepta übertragen, und eine Wiederholung wird ein Jahr lang verfügbar sein. Telefonteilnehmer müssen sich online registrieren, um die Einwahldaten und eine persönliche PIN für den Zugang zu erhalten.
- None.
- None.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212183421/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
When will Sarepta Therapeutics (SRPT) release Q4 and full-year 2024 earnings?
What time is Sarepta's (SRPT) Q4 2024 earnings call?
How can investors access Sarepta's (SRPT) Q4 2024 earnings call?
How long will Sarepta's (SRPT) Q4 2024 earnings call replay be available?
